First-line biologic not cost effective versus triple therapy for RA
First-line biological therapy with etanercept and methotrexate does not appear to be cost effective compared with triple therapy in patients with active rheumatoid arthritis (RA), according to findings of a cost-utility analysis of data from the 48-week RACAT (Rheumatoid Arthritis Comparison of Active Therapies) study published in Annals of Internal Medicine.1 A within-trial analysis of RACAT trial data and a decision-analytic model were used to evaluate the cost effectiveness of first-line treatment with etanercept + methotrexate compared with triple therapy with conventional disease-modifying antirheumatic drugs (cDMARDs; sulfasalazine, hydroxychloroquine and methotrexate) in patients with active RA unresponsive to methotrexate monotherapy, from Medicare and societal perspectives over 24-week and 50-year (lifetime) time horizons. "The high incremental cost-effectiveness ratios documented by Bansback and colleagues comparing bDMARDs·· with cDMARDs suggest that the difference in effectiveness between the 2 strategies may be too small to justify the large difference in cost . . . promoting small improvements at any cost, at levels above those well-accepted by U.S. willingness-to-pay thresholds, may further strain our limited resources and limit access to care not only for patients with RA but also for those with other chronic conditions," commented Drs Rosina and Katz, from Brigham and Women's Hospital, Boston, in an accompanying editorial published in Annals of Internal Medicine.2 * 2014 US dollars *· biological DMARDs 1..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2017 |
|---|---|
| Enthalten in: |
PharmacoEconomics & outcomes news - (2017), 783, Seite 18-18 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| BKL: | |
|---|---|
| Themen: |
Cost analysis |
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC1999598237 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1999598237 | ||
| 003 | DE-627 | ||
| 005 | 20230512080446.0 | ||
| 007 | tu | ||
| 008 | 171228s2017 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a PQ20171228 |
| 035 | |a (DE-627)OLC1999598237 | ||
| 035 | |a (DE-599)GBVOLC1999598237 | ||
| 035 | |a (PRQ)proquest_journals_19733910220 | ||
| 035 | |a (KEY)0248955420170000000078300018firstlinebiologicnotcosteffectiveversustriplethera | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 070 |a 610 |q DE-600 |
| 084 | |a PHARM |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 245 | 1 | 0 | |a First-line biologic not cost effective versus triple therapy for RA |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a First-line biological therapy with etanercept and methotrexate does not appear to be cost effective compared with triple therapy in patients with active rheumatoid arthritis (RA), according to findings of a cost-utility analysis of data from the 48-week RACAT (Rheumatoid Arthritis Comparison of Active Therapies) study published in Annals of Internal Medicine.1 A within-trial analysis of RACAT trial data and a decision-analytic model were used to evaluate the cost effectiveness of first-line treatment with etanercept + methotrexate compared with triple therapy with conventional disease-modifying antirheumatic drugs (cDMARDs; sulfasalazine, hydroxychloroquine and methotrexate) in patients with active RA unresponsive to methotrexate monotherapy, from Medicare and societal perspectives over 24-week and 50-year (lifetime) time horizons. "The high incremental cost-effectiveness ratios documented by Bansback and colleagues comparing bDMARDs·· with cDMARDs suggest that the difference in effectiveness between the 2 strategies may be too small to justify the large difference in cost . . . promoting small improvements at any cost, at levels above those well-accepted by U.S. willingness-to-pay thresholds, may further strain our limited resources and limit access to care not only for patients with RA but also for those with other chronic conditions," commented Drs Rosina and Katz, from Brigham and Women's Hospital, Boston, in an accompanying editorial published in Annals of Internal Medicine.2 * 2014 US dollars *· biological DMARDs 1. | ||
| 650 | 4 | |a Rheumatoid arthritis | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Internal medicine | |
| 650 | 4 | |a Health care access | |
| 650 | 4 | |a Cost analysis | |
| 650 | 4 | |a Medicine | |
| 773 | 0 | 8 | |i Enthalten in |t PharmacoEconomics & outcomes news |d Auckland : Wolters Kluwer Health Adis, 1996 |g (2017), 783, Seite 18-18 |w (DE-627)193388901 |w (DE-600)1308910-9 |w (DE-576)435516213 |x 1173-5503 |7 nnns |
| 773 | 1 | 8 | |g year:2017 |g number:783 |g pages:18-18 |
| 856 | 4 | 2 | |u https://search.proquest.com/docview/1973391022 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.40 |q AVZ |
| 951 | |a AR | ||
| 952 | |j 2017 |e 783 |h 18-18 | ||